←
Bhavana Pothuri1,442 posts
Bhavana Pothuri avatar✓

Bhavana Pothuri ✓

@BPothuri

Gynecologic Oncologist, parent, advocate for patients with Gyn cancer. Opinions are mine not NYU Langone School of Medicine

◷ Joined March 2013▧ 130 Photos and videos
NRG Oncology avatar
⟳ Bhavana Pothuri retweeted
NRG Oncology@NRGonc·Nov 7

🔬Happy Birthday Marie Curie, a trailblazer whose groundbreaking discoveries transformed science & medicine, her legacy continues to inspire generations of researchers. We carry that spirit forward thru innovative research aimed at improving outcomes for patients. #WeWhoCurie Day

Post attachment
Giuseppe Caruso, MD PhD avatar
⟳ Bhavana Pothuri retweeted
Giuseppe Caruso, MD PhD@gcarusomd·Nov 8

Rina-S is coming in the PROC setting, so what happens to MIRV? 🤔 Genmab has announced positive topline results from the phase 3 RAINFOL-02 trial in PROC: Rina-S vs investigator’s choice CHT improved both PFS (HR 0.29) and OS (HR 0.43). 👉 The most interesting part for me is the primary analysis set (PAS), where FRα-high patients had to be pretreated with MIRV: PFS HR 0.33 and OS HR 0.44. Both drugs target FRα, but they are not the same: 🔹 MIRV: tubulin payload, works only in FRα-high tumors 🔹 Rina-S: TOP1i payload, active across FRα levels and apparently also after MIRV 💡 A hypothesis: the order matters? ✅ MIRV first → Rina-S next: MIRV clears the FRα-high cells, and Rina-S can still hit the FRα-low ones that are left. ❌ Rina-S first → MIRV next: very unlikely to work, as little FRα-high disease should be left. And if GLORIOSA trial is positive, MIRV could move earlier, to maintenance in PSOC, with Rina-S kept for PROC. Of course, this “ADC-opoly” board in ovarian cancer is getting crowded, with many more ADCs coming across all settings (1L, PSOC, PROC) and different targets… Things are about to get very complex 🤯 but, on the bright side, there will be more and more options for our patients... even beyond ADCs. @oncodaily - @OncoAlert - @DrKatyMoore - @GynMe4

Post attachmentPost attachmentPost attachment
Oncology Tube avatar
⟳ Bhavana Pothuri retweeted
Oncology Tube@oncologytube·Nov 2

VIDEO: ESMO 2026 — after platinum + PD-(L)1 in endometrial cancer, is a TROP2 ADC next? TroFuse-005: sac-TMT OS 19.0 vs 12.1 mo, HR 0.68 🧬🎯 👉 oncologytube.com/sacituzumab… 🔹 Phase 3, n=776: sacituzumab tirumotecan vs physician's choice (doxorubicin or paclitaxel) 🔹 BICR PFS 7.2 vs 3.9 mo (HR 0.59); ORR 35.1% vs 17.3% 🔹 Grade ≥3 AEs 69% vs 57%; treatment-related deaths <1% per arm Investigational in the US: FDA priority review, PDUFA June 15, 2027. Presidential LBA11 + The Lancet (Oct 26, 2026). @OncoAlert @BPothuri @GynCancerMD @rne_md @ShannonWestin @DrKatyMoore @PamSolimanMD @amandanfader @MirzaCPH @karenluMD @AngelesSecord @nicoleflemingmd @AmirJazaeri @RSalaniMD @FBackesMD @leitaomd @KatherineFuh @DrTewari @pedroramirezMD @ggardnermd @DebbieRic23 @David_Cohn_MD @StephanieLheur5 @JordynSilvs @DrBarbiOnc @drteplinsky @AinhoaMada @Ilaria_Colombo_ @mdslightfoot @JCohenMD @EmmaBarberMD @Britdavidsonmd @BarbaraAGoff @matei_dem @aaronshafer99 #ESMO26 #EndometrialCancer #GynOnc #ADC #OncologyTube #MedOnc

Post attachment
NRG Oncology avatar
⟳ Bhavana Pothuri retweeted
NRG Oncology@NRGonc·Nov 6

Application Deadline Approaching! NRG Oncology is currently accepting applications for travel awards to #NRG2027 in Las Vegas! Application window closes November 9th. More information can be found at ow.ly/oJEj50ZZ617

Post attachment
Mark Cuban avatar
⟳ Bhavana Pothuri retweeted
Mark Cuban@mcuban·Nov 5

For those who say it’s time for universal care. I am all for it. It would be nice if we could find a way to reduce the cost of care and make it available to everyone, for anything. But it will take work to get there. Other countries with Universal Care make “Most Things available to All People”. It’s not perfect. In our country, we make “Everything available to Most People”. The question for this country, unlike others, is how we can make the best possible care and therapies, regardless of cost, to everyone ? Read @AbdulElSayed ‘s book on Medicare for All. He wisely had more questions than answers. Medicare for All ? Global Budgets ? Or something else ? It’s a difficult path from where we are to “E4E” Healthcare. ?Everything for Everyone) My hope is that we can put together a Simpson Bowles type, Blue Ribbon Commission. One that includes representatives of all stakeholders. From all different type of patients. Including rare disease parents. Rural and Urban Hospitals. The most expensive hospitals that offer unique care. Pharma companies that offer everything from genetics to Cell and Gene Therapies. You get the point Some people think we can just tell all those working in the healthcare system what to do. That’s the fastest way for this to fail. We need to be as close as we can to being on the same page. And we need to figure out a non partisan manner of running our American version of Universal Care. No reason we can’t start now

Dr. Anthony Letai avatar
⟳ Bhavana Pothuri retweeted
Dr. Anthony Letai@NCIDirector·Nov 5

Cancer research runs on people who are just starting out. In 2026, @theNCI funded a record 147 new awards for early-stage investigators. I am looking forward to seeing what they discover and which future breakthroughs start in their labs.

Post attachment
NYU Department of Medicine avatar
⟳ Bhavana Pothuri retweeted
NYU Department of Medicine@NYULH_DeptofMed·Nov 5

We are pleased to welcome Michelle Kang Kim, MD, PhD (@MichelleKimMD), a distinguished gastroenterologist and NIH-funded clinician-scientist, as the new Chair of the Department of Medicine @nyugrossman! Dr. Kim is renowned for her leadership, transformative research on gastrointestinal (GI) carcinoid and neuroendocrine tumors, and predictive models for the early detection of GI cancers. We are proud to welcome her to @NYULH_DeptofMed Press Release: bit.ly/4iZPJTa #Exceptionalism #Leadership #TranslationalResearch #ClinicalInnovation #MedTwitter #GITwitter

Post attachment